Please login to the form below

Not currently logged in

trastuzumab emtansine

This page shows the latest trastuzumab emtansine news and features for those working in and with pharma, biotech and healthcare.

AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

The $6.9bn deal, funded in part by an equity placement of approximately $3.5bn, includes a sizeable $1.35bn upfront payment which reflects the fact that the ADC – trastuzumab deruxtecan ... DS-8201 is currently in phase 3 testing for HER2-positive

Latest news

More from news
Approximately 5 fully matching, plus 43 partially matching documents found.

Latest Intelligence

  • An eye towards the biobetter in South Korea An eye towards the biobetter in South Korea

    It was noteworthy that the Celltrion's announcement happened to coincide with Roche's clinical data presentation of its Herceptin biobetter, Trastuzumab-emtansine (T-DM1). . ... CT-P26. Celltrion. Trastuzumab-dolastatin 10 antibody drug conjugate. S

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...